NLM Digital Collections

Search

Start Over Subjects Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy ✖Remove constraint Subjects: Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy Titles Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment ✖Remove constraint Titles: Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment

Refine by:

more »

  • Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment1